Knowledge Sharing

On June 12, 2026, XKH001, an anti-IL-25 monoclonal antibody injection, completed the first patient dosing in its Phase II clinical trial for COPD. This milestone signifies a key breakthrough of the IL-25 target in respiratory disease therapy, and also leads the industry to look into the development potential of nanobodies, the cutting-edge next-generation antibody technology.

Published online May 12, 2026, in BMC Biotechnology, an international team led by the Pasteur Institute of Iran has developed two humanized anti-VEGF nanobody variants—MHNb136 and MHNb256—with affinity superior to bevacizumab, providing promising next-generation anti-angiogenic candidates for ocular diseases and cancer.

Recently, a major breakthrough has been announced in the biopharmaceutical industry: SIM0613, an innovative LRRC15-targeted antibody-drug conjugate (ADC) developed by Simcere Zaiming, has been officially approved for clinical trials. With outstanding preclinical data, this drug has secured an ...

BackgroundTreatment of advanced solid tumors remains highly challenging. Conventional chemotherapy and targeted therapies suffer from poor specificity, frequent drug resistance, and severe side effects. Most patients lose the chance for curative surgery and face poor prognosis. Combining preci...

Cystic fibrosis (CF) is a common life-threatening autosomal recessive disorder affecting millions worldwide. The F508del-CFTR (cystic fibrosis transmembrane conductance regulator) mutation is the primary pathogenic culprit, present in approximately 90% of CF patients. For decades, repairing the p...

Zai Lab and Boehringer Ingelheim have partnered to develop DLL3-targeted dual therapies for ES-SCLC and NEC. The collaboration combines Obrixtamig and Zai Lab’s DLL3 ADC, spotlighting DLL3 as a key target and nanobody technology’s transformative role in antibody drug development.

Recently, nanobody applications in oncology have achieved a major breakthrough: JSKN016, a bispecific ADC independently developed by Alphamab Oncology, has dosed its first patient in a Phase III trial. This milestone signifies that nanobody‑enabled innovative drug R&D has entered a critical phase, highlighting the clinical value and application potential of nanobodies.

A Chinese team’s latest study in Nature Communications developed BA2-1A10, the world’s first potent broad‑spectrum bispecific anti‑Ebola agent based on camel nanobodies. It overcomes the single‑strain limitation of conventional antibodies, shows excellent efficacy in vitro and in vivo, and highlights the great potential of nanobodies.

Solid tumor innovative therapy advances: US FDA approves IND for injectable HDM2024, an EGFR/HER3 dual-target Bs-ADC. A Phase I trial for advanced solid tumors will launch in the US. The drug’s unique dual-target synergy brings a new option for drug-resistant solid tumors, and this article analyzes its core mechanism and clinical value via target interpretation.

In March 2026, the Chinese innovative drug sector received exciting news — MWX401 Injection, an independently developed small interfering

A recent international team reported in Nature Communications the first mGlyR-targeting nanobody Nb20. Intranasal administration showed rapid, potent, and long-lasting antidepressant effects in mice, validating mGlyR as a novel target and establishing a new paradigm for treating neuropsychiatric disorders with nanobodies.

PD-1 immunotherapy is a classic cancer paradigm but limited by low response and resistance. PD-L1 has emerged as a core next‑generation immunotherapy target. Nanobodies, combined with 2026 advances, are overcoming clinical bottlenecks. Here we review PD-L1’s value, latest progress, and how nanobodies unlock its full potential.